AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Description: AcelRx Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct's pharmaceuticals report, "AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the AcelRx Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, AcelRx Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from AcelRx Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- AcelRx Pharmaceuticals, Inc. - Brief AcelRx Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AcelRx Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of AcelRx Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AcelRx Pharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate AcelRx Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AcelRx Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AcelRx Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AcelRx Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AcelRx Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Contents:

List of Tables
List of Figures
AcelRx Pharmaceuticals, Inc. Snapshot
AcelRx Pharmaceuticals, Inc. Overview
Key Information
Key Facts
AcelRx Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
AcelRx Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
AcelRx Pharmaceuticals, Inc. – Pipeline Products Glance
AcelRx Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
AcelRx Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
AcelRx Pharmaceuticals, Inc. – Drug Profiles
(sufentanil + triazolam)
Product Description
Mechanism of Action
R&D Progress
ARX-0
Product Description
Mechanism of Action
R&D Progress
ARX-0
Product Description
Mechanism of Action
R&D Progress
AcelRx Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
AcelRx Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action
AcelRx Pharmaceuticals, Inc. – Recent Pipeline Updates
AcelRx Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
AcelRx Pharmaceuticals, Inc., Recent Developments
AcelRx Pharmaceuticals, Inc.- Press Release
May 02, 2013: AcelRx Pharma Presents Positive Clinical Data For Sufentanil NanoTab PCA System At ASRA Medical Meeting
Apr 24, 2013: AcelRx Pharma Meets Primary Endpoint In Phase II Clinical Trial Of ARX-04 For Acute Pain
Mar 04, 2013: AcelRx Pharma Meets Primary Endpoint In Pivotal Phase III Study Of Sufentanil NanoTab PCA System For Post-Operative Pain
Feb 19, 2013: AcelRx Pharma Completes Dosing In Phase II Study Of ARX-04 Sufentanil Acute Pain NanoTab
Feb 19, 2013: AcelRx Pharma Provides Clinical Trial Update On Sufentanil NanoTab PCA System
Oct 01, 2010: AcelRx Completes End-Of-Phase II Meeting With FDA For ARX-02 For Treatment Of Cancer Pain
May 25, 2010: AcelRx Announces Positive Phase II Results Of ARX-02 Sufentanil NanoTab For Treatment Of Cancer Breakthrough Pain
Financial Deals Landscape
AcelRx Pharmaceuticals, Inc., Deals Summary
AcelRx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
AcelRx Pharma Raises US$8 Million In Venture Financing
AcelRx Pharma Secures US$14.8 Million In Financing Round
AcelRx Pharma Secures US$12 Million In Financing
AcelRx Pharma Secures US$20.21 Million In Venture Financing
Equity Offering
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million
AcelRx Pharma Completes Private Placement Of Units For US$10 Million
AcelRx Pharma Completes IPO Of US$40 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
AcelRx Pharmaceuticals, Inc., Key Information
AcelRx Pharmaceuticals, Inc., Key Facts
AcelRx Pharmaceuticals, Inc. – Pipeline by Indication, 2013
AcelRx Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013
AcelRx Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013
AcelRx Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013
AcelRx Pharmaceuticals, Inc. – Phase III, 2013
AcelRx Pharmaceuticals, Inc. – Phase II, 2013
AcelRx Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013
AcelRx Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2013
AcelRx Pharmaceuticals, Inc. – Recent Pipeline Updates, 2013
AcelRx Pharmaceuticals, Inc., Deals Summary
AcelRx Pharma Raises US$8 Million In Venture Financing
AcelRx Pharma Secures US$14.8 Million In Financing Round
AcelRx Pharma Secures US$12 Million In Financing
AcelRx Pharma Secures US$20.21 Million In Venture Financing
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million
AcelRx Pharma Completes Private Placement Of Units For US$10 Million
AcelRx Pharma Completes IPO Of US$40 Million

List of Figures
AcelRx Pharmaceuticals, Inc. – Pipeline by Indication, 2013
AcelRx Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013
AcelRx Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013
AcelRx Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013
AcelRx Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2557745/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Web Address: http://www.researchandmarkets.com/reports/2557745/
Office Code: SCD2Y3YU

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 4500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World